EUVIMEDEUVIMED entdecken
KommentarOpen Access · CC BY-NC-ND 4.0

Transcatheter Edge-to-Edge Repair for Secondary Mitral Regurgitation with Third-Generation Devices in Heart Failure Patients – Results from the Global EXPAND Post-Market Study

Mathias Orban iD, Wolfgang Rottbauer, Mathew Williams, Paul Mahoney, Ralph Stephan von Bardeleben, Matthew J Price, Carmelo Grasso, Philipp Lurz, Jose L Zamorano, Federico M Asch, Francesco Maisano, Saibal Kar und 1 weitere

European Journal of Heart Failure · 2023

DOI: 10.1002/ejhf.2770 ↗

Kurz gefasst

Kommentar in der Zeitschrift European Journal of Heart Failure, 2023. Verfasst von Mathias Orban und 12 weiteren Autor:innen. Beteiligte Einrichtung: Medizinische Klinik I, Ludwig-Maximilians Universität, Munich, Germany. Hauptthemen laut MEDLINE: Mitral Valve Insufficiency, Heart Failure, Heart Valve Prosthesis Implantation. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Abbott, Abbott Laboratories.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Mitral valve transcatheter edge-to-edge repair is a guideline-recommended treatment option for patients with secondary mitral regurgitation (SMR). The purpose of this analysis was to report contemporary real-world outcomes in SMR patients treated with third-generation MitraClip systems. Methods and results EXPAND is a prospective, multicentre, international, single-arm study with 1041 patients treated for mitral regurgitation (MR) with MitraClip NTR/XTR, with 30-day and 1-year follow-up. All echocardiograms were analysed by an independent echocardiographic core lab. Study outcomes included procedural outcomes, durability of MR reduction, and major adverse events including all-cause mortality and heart failure hospitalizations (HFH). A subgroup of 413 symptomatic patients (age 74.7 ± 10.1 years, 58% male) with severe SMR were included. MR reduction to MR ≤ 1+ and MR ≤ 2+ was achieved in 93.0% and 98.5% of patients, respectively, which was sustained at 1-year follow-up. All-cause mortality was 17.7% at 1-year- follow-up, and the combined endpoint of all-cause mortality or first HFH occurred in 34% of patients. This combined endpoint was significantly less frequently observed in MR ≤ 1+ patients (Kaplan–Maier estimates: 29.7% vs. 69.6% for MR ≤ 1+ vs. MR ≥ 2 +; p < 0.0001). New York Heart Association (NYHA) functional class improved significantly from baseline (NYHA ≤ II: 17%) to 1-year follow-up (NYHA ≤ II: 78%) (p < 0.0001). While MR reduction was comparable between NTR-only vs. XTR-only treated patients, less XTR clips were required for achieving MR reduction.

Conclusions

Under real-world conditions, optimal sustained MR reduction to MR ≤ 1+ was achieved in a high percentage of patients with third-generation MitraClip, which translated into symptomatic improvement and low event rates. These results appear to be comparable with recent randomized clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mitral Valve InsufficiencyHeart FailureHeart Valve Prosthesis ImplantationHumansMaleMiddle AgedAgedAged, 80 and overFemaleMitral ValveProspective StudiesTreatment OutcomeCardiac Catheterization

Stichwörter der Autor:innen

Heart failureMitraClipMitral regurgitationMitral valve transcatheter edge-to-edge repairSecondary mitral regurgitationTranscatheter mitral valve repair

Autor:innen und Institutionen

  • Medizinische Klinik I, Ludwig-Maximilians Universität, Munich, Germany.
  • Munich Heart Alliance, Partner site German Centre for Cardiovascular Research (DZHK), Munich, Germany.
  • Department of Internal Medicine II, Ulm University Medical Center, Ulm, Germany.
  • Heart Valve Center, New York University Langone Health, New York, NY, USA.
  • Sentera Heart and Valve and Structural Disease Center, Norfolk, VA, USA.
  • Department of Cardiology, University Medical Center of Mainz, Mainz, Germany.

ORCID-Profile: Mathias Orban

Förderung

  • Abbott
  • Abbott Laboratories

Zitieren

APA

Orban, M., Rottbauer, W., Williams, M., Mahoney, P., von Bardeleben, R. S., Price, M. J., Grasso, C., Lurz, P., Zamorano, J. L., Asch, F. M., Maisano, F., Kar, S., & Hausleiter, J. (2023). Transcatheter Edge-to-Edge Repair for Secondary Mitral Regurgitation with Third-Generation Devices in Heart Failure Patients – Results from the Global EXPAND Post-Market Study. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.2770

Vancouver

Orban M, Rottbauer W, Williams M, Mahoney P, von Bardeleben RS, Price MJ, et al. Transcatheter Edge-to-Edge Repair for Secondary Mitral Regurgitation with Third-Generation Devices in Heart Failure Patients – Results from the Global EXPAND Post-Market Study. European Journal of Heart Failure. 2023. doi:10.1002/ejhf.2770

BibTeX
@article{Orban2023,
  author = {Orban, Mathias and Rottbauer, Wolfgang and Williams, Mathew and Mahoney, Paul and von Bardeleben, Ralph Stephan and Price, Matthew J and Grasso, Carmelo and Lurz, Philipp and Zamorano, Jose L and Asch, Federico M and Maisano, Francesco and Kar, Saibal and Hausleiter, Jörg},
  title = {Transcatheter Edge-to-Edge Repair for Secondary Mitral Regurgitation with Third-Generation Devices in Heart Failure Patients – Results from the Global EXPAND Post-Market Study},
  journal = {European Journal of Heart Failure},
  year = {2023},
  doi = {10.1002/ejhf.2770}
}
Kostenlos starten →